Pamrevlumab not checked

Kyntra Bio · FG-3019

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
24 active
38 in total · 29 in the EU
Targets
—
None known yet

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Pamrevlumab per dose and schedule specified in the arm description”In the company’s words, NCT04371666 on ClinicalTrials.gov
Tested for
Duchenne Muscular Dystrophy (3 trials), Idiopathic Pulmonary Fibrosis (3 trials), Pancreatic Cancer Non-resectable, COVID-19, Pancreatic Cancer (Unresectable)
Main trialPhase 3
“To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids in participants with non-ambulatory Duchenne muscular dystrophy (age 12 years and older).”In the company’s words, NCT04371666 on ClinicalTrials.gov
Other names
FG-3019 · Gemzar · Abraxane · Eloxitan · Leucovorin · Camptosar · Recombinant human monoclonal antibody

Other drugs for Duchenne Muscular Dystrophy

All 23 drugs for Duchenne Muscular Dystrophy

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials38

TrialPhaseCompletesWhat it tests
Phase 3Terminated 13 Feb 2023 Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Phase 3Terminated 20 Mar 2023 Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Phase 3Terminated 12 Jun 2023 Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD
Phase 3Terminated 4 Sep 2023 Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Phase 3Completed 11 Jun 2024 Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Phase 2Terminated 7 May 2020 Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
Phase 2Terminated 22 Mar 2021 Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease
Phase 1/2Completed 15 Dec 2021 A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Phase 1Completed not given Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis
Phase 3Authorised not given NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (The NEEDS Trial)
Phase 3Authorised not given Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: a randomized controlled trial - METAPANC
Phase 2Ended not given Phase II study evaluating Holmium-166 TARE followed by maIntenance Therapy in liver limited unresectable colorectal cancer patients after first-lIne chemotherapy and target agents: The HAITI study.
Phase 3Authorised not given DOSAgE study: A multicenter randomized phase III trial of DOSe-reduced Chemotherapy for Advanced Colorectal Cancer in Older patients
Phase 3Authorised not given PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRESECTABLE pMMR AND IMMUNOSCORE IC-HIGH METASTATIC COLORECTAL CANCER PATIENTS. The AtezoTRIBE2 Study
Phase 2Authorised not given ENCORAFENIB+CETUXIMAB BEYOND PROGRESSION IN COMBINATION WITH FOLFIRI IN PATIENTS WITH BRAF V600E MUTATED METASTATIC COLORECTAL CANCER PROGRESSING ON ENCORAFENIB + CETUXIMAB
Phase 2Ended not given ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in patients with low risk localized gastroesophageal adenocarcinoma (study PRODIGE/FRENCH 39)
Phase 2Authorised not given Neo-adjuvant FOLFOXIRI and chemoradiotherapy for high risk (“ugly”) locally advanced rectal cancer.
Phase 2Authorised not given OPTIMISE OPTIMIzation of treatment SElection and follow up in oligometastatic colorectal cancer – a ctDNA guided phase II randomized approach
Phase 2Authorised not given DOVIPA, a phase II study evaluating efficacy and safety of DOstarlimab and oral VItamin D3 with folinic acid, 5FU, Irinotecan plus oxalipaltin (mFOLFIRINOX) in non pretreated metastatic PAncreatic Cancer.
Phase 2Authorised not given Using organoids to predict efficacy of adjuvant treatment to improve outcome in resectable pancreatic cancer (UNITEPANC)
Phase 3Authorised not given NORAD01 - Non inferiority multicenter phase III randomized trial comparing preoperative chemotherapy only to chemotherapy followed by chemoradiotherapy for locally advanced resectable rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE).
Phase 1/2Authorised not given Phase Ib-II, non-randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with modFOLFIRINOX for front-line treatment of metastatic pancreatic adenocarcinoma
Phase 2/3Authorised not given GEMFOX - Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for FOLFIRINOX
Phase 3Authorised not given Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer (PelvEx II)
Phase 2Authorised not given Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoadjuvant therapy for locally advanced rectal cancer: the ShorTrip trial
Phase 2Halted not given ENGIC - 01 COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a doublet/triplet chemotherapy with advanced unresectable KRAS G12C mutated colorectal adenocarcinoma
Phase 2Ended not given Phase II Study Of Tarlatamab Alone Or In Combination With Chemotherapy In Advanced Neuroendocrine Carcinomas Of The Digestive System Or Unknown Primary Origin
Phase 3Authorised not given An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature (ESPAC-6)
Phase 2Authorised not given Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial)
Phase 3Authorised not given Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer.
Phase 2Authorised not given Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer : a multicentre, randomised, phase 2 trial (Nordic Pancreatic Cancer Trial (NORPACT) – 1
Phase 3Authorised not given A Phase III, Randomized, Open-Label Clinical Study of Napabucasin in Combination with FOLFIRI and Best Supportive Care (BSC) Versus Napabucasin plus BSC in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)
Phase 2Not authorised not given PRODIGE 113 (FFCD 2314) – REWENEC – 01 STUDY Randomized trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI with a hybrid synthetic control arm in second line treatment of metastatic neuroendocrine carcinoma of gastro-enteropancreatic or unknown origin. Phase II comparative randomized study – multicentric
Phase 3Authorised not given CIRCULATE III - Tailoring the decision for adjuvant chemotherapy using circulating tumour DNA, in patients with stage III colorectal cancer
Phase 1/2Authorised not given A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
Phase 3Authorised not given Multicentre, open-label, randomised, controlled, parallel-arms, phase III, clinical trial of Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer: MEND-IT II
Phase 2Authorised not given IKF-099/D-FLOT-TNT Total Neoadjuvant Treatment with preoperative FLOT/Durvalumab plus postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma
Phase 2Authorised not given ATTENUATION2 - A multicenter, randomized phase II study of the efficacy and safety of de-escalation versus standard adjuvant treatment in patients with low-risk localized gastroesophageal adenocarcinoma (PRODIGE99/FRENCH 39 study).
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Pamrevlumab

Following is part of Solo: you see every change to Pamrevlumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in